US · ADPT
Adaptive Biotechnologies Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Seattle, WA 98109
- Website
- adaptivebiotech.com
Price · as of 2025-12-31
$14.27
Market cap 2.46B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $37.10 | +159.99% |
| Intrinsic Value(DCF) | $54.36 | +280.94% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $27.04 | $106.48 | $54.96 | $0.88 | $0.00 |
| 2020 | $41.49 | $42.92 | $3.47 | $0.00 | $0.00 |
| 2021 | $11.00 | $29.55 | $2.12 | $0.00 | $0.00 |
| 2022 | $8.00 | $25.04 | $1.08 | $0.00 | $0.00 |
| 2023 | $3.65 | $23.48 | $0.00 | $0.00 | $0.00 |
| 2024 | $7.35 | $26.02 | $0.00 | $0.00 | $0.00 |
| 2025 | $16.12 | $37.10 | $15.87 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Adaptive Biotechnologies Corporation's (ADPT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $37.10
- Current price
- $14.27
- AI upside
- +159.99%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$54.36
+280.94% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADPT | Adaptive Biotechnologies … | $14.27 | 2.46B | +160% | +281% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| CDTX | Cidara Therapeutics, Inc. | $221.38 | 5.61B | -67% | -96% | — | +934% | -0.88 | 0.92 | 117.83 | 0.20 | -0.22 | 0.92 | -6557.49% | -13811.92% | -13319.76% | -218.99% | 567.59% | -120.52% | 0.02 | — | 4.25 | 3.86 | 1.06 | 40952.00% | -9800.00% | 67021.00% | -117.59% | -3.56 | 569.40% | 0.00% | 0.00% | 103.41% | 0.20 | 0.20 | -28.25 | -4.03 |
| CPRX | Catalyst Pharmaceuticals,… | $23.08 | 2.84B | +180% | +200% | -28% | +106% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| IRON | Disc Medicine, Inc. | $66.62 | 2.51B | — | — | — | — | -11.07 | 3.17 | — | -7.50 | -21.38 | 3.17 | 0.00% | — | — | -35.86% | 717.87% | -32.55% | 0.00 | -65.43 | 21.94 | 21.59 | 0.43 | 5177.00% | — | 9202.00% | -7.72% | -4.92 | 551.51% | 0.00% | 0.00% | 0.00% | -6.61 | -8.60 | — | 20.31 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| TARS | Tarsus Pharmaceuticals, I… | $75.52 | 3.21B | +33% | +191,318% | -100% | — | -48.71 | 9.42 | 7.17 | -54.31 | — | 9.63 | 93.20% | -15.72% | -14.72% | -23.39% | -558.70% | -14.14% | 0.27 | -7.94 | 3.85 | 3.72 | 1.68 | -4821.00% | 14671.00% | -7363.00% | -0.69% | -0.09 | -175.63% | 0.00% | 0.00% | 2.09% | -41.03 | -130.51 | 6.45 | 9.02 |
| ZLAB | Zai Lab Limited | $19.22 | 2.13B | +50% | -49% | — | — | -11.49 | 2.82 | 4.38 | -9.81 | — | 3.16 | 58.60% | -49.86% | -38.15% | -22.56% | -97.09% | -14.89% | 0.31 | -44.05 | 2.45 | 1.91 | 2.88 | -3846.00% | 1533.00% | -4251.00% | -7.88% | -0.36 | -68.36% | 0.00% | 0.00% | 7.89% | -6.77 | -9.77 | 3.37 | -0.13 |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- CEO
- Chad Robins
- Employees
- 619
- Beta
- 2.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($54.36 ÷ $14.27) − 1 = +280.94% (DCF, example).